Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 78   

Articles published

ARNA 4.67 -0.10 (-2.10%)
price chart
Arena's Sales Pace For Belviq - What Is Needed (ARNA)
With Eisai and Arena Pharmaceuticals (NASDAQ:ARNA) announcing new and less expensive pricing for Belviq, investors will want to be keen on the new dynamics that such an action presents.
Arena (ARNA) Predicts Lower BELVIQ Revenue In Fourth Quarter Of 2014  Bidness ETC
Eisai Launches New Savings Card to Increase Access and Affordability of ...  Pharmacy Times
Stock in Focus : Arena Pharmaceuticals Inc (NASDAQ:ARNA)
Arena Pharmaceuticals Inc (NASDAQ:ARNA) (TREND ANALYSIS) is expected to report earnings per share of $-0.24 for the current fiscal year, as per consensus of analysts.
Company Updates: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...  Realist Investor
Market News: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), LRAD Corp ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) disclosed that it preliminarily expects Eisai's net product sales of Belviq for Q4 to decrease by 35%-45% relative to the $16.8M for Q3.
Belviq revenues drop substantially in Q4 due to discounting (ARNA)  Seeking Alpha
Arena Pharma (ARNA) Sees Eisai's BELVIQ Sales Down 35% - 45 ...
Arena Pharmaceuticals Announces Public Offering of Common Stock
20, 2015 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
Company Watch: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Apartment ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Monday said it has begun patient dosing in a Phase 2 clinical trial of ralinepag, an oral, non-prostanoid prostacyclin receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH).
Arena Pharmaceuticals Earns Sector Perform Rating from Analysts at RBC ...
Arena Pharmaceuticals, Inc. logo RBC Capital started coverage on shares of Arena Pharmaceuticals (NASDAQ:ARNA) in a research report released on Thursday morning, TheFlyOnTheWall.
3 Falling Stocks: Key Energy Services, Inc.(KEG), Arena Pharmaceuticals, Inc ...  NIS
Stocks Underperform for the Week: Arena Pharmaceuticals Inc , Gerdau SA  Ashburn Daily
Arena Pharmaceuticals (ARNA) in Focus: Stock Falls 5.7%
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) saw a big move last session, as the company's shares fell by nearly 6% on the day.
Arena Pharmaceuticals (ARNA) in Focus: Stock Falls 5.7% - Tale of the Tape  Nasdaq
Biotech Gainers: Kite Pharma (KITE), Exelixis (EXEL), Arena Pharmaceuticals ...
Kite Pharma Inc (NASDAQ:KITE) released that the Company has expanded its contract with Tel Aviv Sourasky Medical Center to research and develop novel approaches to CAR T cell therapy, the technology underlying Kite's most advanced programs in ...
Arena's Belviq Prescriptions Fall: More Publicity Is Needed
New prescription numbers have been released by Symphony for Belviq (see Table 1), the anti-obesity agent from Arena Pharmaceuticals (NASDAQ:ARNA). ... Eisai is the sole company engaging in direct-to-consumer advertising (DTCA). Vivus is financially ...
A Deeper Look At Arena's Belviq Pricing
It has certainly been an interesting start to 2015 when you look at Arena Pharmaceuticals (NASDAQ:ARNA). The equity closed out 2014 with a stock price of about ... Part of the recent news flow for Arena has been an announcement of new pricing for the ...
Biotech Industry Again Garb Market Attentions- Arena Pharmaceuticals, Inc ...  StreetWise Report
Most Volatile Healthcare Stocks: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...  eMarketsDaily